Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV AbbVie Inc. daily Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E16.86 EPS (ttm)5.08 Insider Own0.08% Shs Outstand1.56B Perf Week-1.55%
Market Cap133.77B Forward P/E9.82 EPS next Y8.72 Insider Trans-17.79% Shs Float1.49B Perf Month-2.96%
Income7.93B PEG1.00 EPS next Q1.93 Inst Own72.20% Short Float2.03% Perf Quarter-10.52%
Sales32.19B P/S4.16 EPS this Y-2.40% Inst Trans-0.02% Short Ratio4.62 Perf Half Y-14.02%
Book/sh-1.93 P/B- EPS next Y9.65% ROA11.20% Target Price100.58 Perf Year-12.06%
Cash/sh5.62 P/C15.23 EPS next 5Y16.87% ROE- 52W Range77.50 - 125.86 Perf YTD-11.48%
Dividend4.28 P/FCF19.78 EPS past 5Y1.20% ROI17.80% 52W High-31.98% Beta1.68
Dividend %5.00% Quick Ratio1.10 Sales past 5Y9.00% Gross Margin76.30% 52W Low10.46% ATR2.85
Employees30000 Current Ratio1.20 Sales Q/Q17.70% Oper. Margin33.00% RSI (14)41.36 Volatility2.92% 3.23%
OptionableYes Debt/Eq- EPS Q/Q78.30% Profit Margin23.40% Rel Volume0.83 Prev Close87.71
ShortableYes LT Debt/Eq- EarningsNov 02 BMO Payout67.50% Avg Volume6.57M Price85.61
Recom2.60 SMA20-3.81% SMA50-2.64% SMA200-10.43% Volume5,442,351 Change-2.39%
Oct-22-18Reiterated SunTrust Buy $157 → $135
Oct-04-18Reiterated BofA/Merrill Buy $107 → $106
Jun-01-18Downgrade Piper Jaffray Overweight → Neutral
May-30-18Downgrade Credit Suisse Neutral → Underperform
Jan-30-18Reiterated Morgan Stanley Equal-Weight $99 → $131
Jan-29-18Downgrade Leerink Partners Outperform → Mkt Perform
Oct-30-17Reiterated Leerink Partners Outperform $108 → $107
Oct-02-17Upgrade Leerink Partners Mkt Perform → Outperform
Sep-25-17Downgrade UBS Buy → Neutral $79 → $92
Aug-17-17Initiated Evercore ISI Outperform $95
Jun-22-17Upgrade Societe Generale Hold → Buy
Mar-22-17Upgrade Societe Generale Sell → Hold
Oct-31-16Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Mkt Perform $70
Sep-08-16Downgrade JP Morgan Overweight → Neutral
Sep-02-16Initiated Raymond James Outperform $82
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-14-18 07:13PM  [$$] Companies Ramp Up Stock Buybacks as Market Swoon Continues The Wall Street Journal
12:27PM  AbbVie May Yield More Than It Appears GuruFocus.com
Dec-13-18 01:00PM  AbbVie Announces $5 Billion Increase to Stock Repurchase Program PR Newswire
Dec-12-18 10:51AM  5 Pharma Stocks That Could Cure Ailing Portfolios in 2019 InvestorPlace
05:00AM  AbbVie- High Yield at a Low Valuation MoneyShow
Dec-11-18 03:55PM  Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO Zacks
02:20PM  7 Stocks Wall Street Is Souring on Right Now Kiplinger
09:51AM  Bristol-Myers to Study Opdivo in Combo With Vedanta's VE800 Zacks
06:01AM  How Worried Should You Be About AbbVie's $5.8 Billion Boondoggle? Motley Fool
Dec-10-18 05:45PM  AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know Zacks
10:33AM  Dont Punish Gilead Stock for Doing Its Job InvestorPlace
09:13AM  Amgen (AMGN) Continues to Reward Shareholders, Ups Dividend Zacks
Dec-09-18 04:25PM  Here's Why AbbVie Stock Surged 21.1% in November Motley Fool
09:03AM  3 Top Stocks to Buy in December Motley Fool
07:00AM  Did Gilead Sciences Make an $11 Billion Blunder? Motley Fool
Dec-08-18 09:38PM  Is AbbVie Inc (ABBV) A Good Stock To Buy? Insider Monkey
Dec-07-18 01:30PM  AbbVie Falls 4% Investing.com
Dec-06-18 08:39PM  [$$] Congress to Drug Makers: Why Stock Buybacks Over Lowered Drug Prices? The Wall Street Journal
01:28PM  AbbVie Falls 3% Investing.com
10:40AM  AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study Zacks
10:27AM  AbbVie Stock Has a $10 Upside Opportunity Buy It Now InvestorPlace
07:56AM  The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering Benzinga
Dec-05-18 05:23PM  AbbVie halts late-stage trial for lung cancer drug Rova-T Reuters
04:46PM  AbbVie halts late-stage trial for lung cancer drug Rova-T Reuters
04:24PM  Why Oregon can now afford to treat more people with hepatitis C American City Business Journals
04:23PM  Gilead's (GILD) Harvoni and Descovy Get Approval in China Zacks
04:01PM  Phase 3 Trial of Rova-T as Second-line Therapy for Advanced Small-Cell Lung Cancer (TAHOE STUDY) Halted PR Newswire
10:28AM  7 Dividend Aristocrats to Buy for 2019 InvestorPlace
09:38AM  J&J's Blood Cancer Drugs Succeed in Label Expansion Studies Zacks
05:00AM  Timely Ten- Top Values from IQ Trends MoneyShow
Dec-04-18 05:44PM  AbbVie Falls 3% Investing.com
02:39PM  Roche Announces Positive Data on Venclexta/Venclyxto at ASH Zacks
11:52AM  IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR (Fludarabine, Cyclophosphamide and Rituximab) in Previously Untreated and Younger Chronic Lymphocytic Leukemia (CLL) Patients; Late-Breaking Phase 3 Data at ASH 2018 PR Newswire
11:24AM  JNJ-AbbVie cancer drug Imbruvica succeeds in late-stage trial Reuters
10:37AM  JNJ-AbbVie cancer drug Imbruvica succeeds in late-stage trial Reuters
Dec-03-18 02:25PM  AbbVie Stock Could Become a New Happy Pill for Investors InvestorPlace
02:17PM  IMBRUVICA® (ibrutinib) Phase 3 Combination Data with Obinutuzumab Finds Significant Improvement in Progression-Free Survival (PFS) Over Standard Chemoimmunotherapy of Chlorambucil Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) PR Newswire
11:52AM  AbbVie's Imbruvica Achieves Up to 7-Year Progression-Free Survival in Leukemia Patients GuruFocus.com
09:55AM  AbbVie Settles With Pfizer for Humira Biosimilar in U.S. Zacks
09:00AM  AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018 Zacks
07:00AM  Today's Research Reports on Trending Tickers: AbbVie and OPKO Health ACCESSWIRE
Dec-02-18 12:00PM  IMBRUVICA® (ibrutinib) Data in Chronic Lymphocytic Leukemia (CLL) Show up to Seven Years of Progression-free Survival (PFS) in 80 Percent of Previously Untreated Patients, the Longest Follow-up for a Bruton's Tyrosine Kinase Inhibitor to Date PR Newswire
09:30AM  Why Is AbbVie (ABBV) Up 17.5% Since Last Earnings Report? Zacks
Dec-01-18 05:47PM  AbbVie Presents New Data from Phase 3 MURANO Trial of VENCLEXTA®/VENCLYXTO® (venetoclax) in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed the Fixed Treatment Course PR Newswire
Nov-30-18 07:04PM  Delayed Humira Biosimilar Boosts AbbVie's Fair Value Morningstar
05:24PM  U.S. Stocks Sprint Ahead to End a Blockbuster Week Barrons.com
04:16PM  Pfizer Stock Edges Into Buy Zone On AbbVie Deal For Humira Biosimilar Investor's Business Daily
03:26PM  3 Beaten-Down Biotech Stocks to Buy Before the End of 2018 InvestorPlace
03:22PM  AbbVie Rises 3% Investing.com
12:12PM  U.S.-China Trade Talks In Focus, While Just One Stock Sector Stands Out Investor's Business Daily
10:15AM  The New Amazon Blockchain Products Could Be Huge for AMZN InvestorPlace
10:00AM  AbbVie Announces HUMIRA® (adalimumab) Global Patent License with Pfizer PR Newswire
09:56AM  Key Pharma Players With HIV Focus Ahead of World Aids Day Zacks
Nov-28-18 05:45PM  AbbVie (ABBV) Gains But Lags Market: What You Should Know Zacks
12:47PM  3 Themes To Watch As Biopharmas 'Bring Some Excitement' In Blood Cancer Investor's Business Daily
08:41AM  Vertex's (VRTX) Triple Combo Cystic Fibrosis Studies Succeed Zacks
08:24AM  3 Top Stocks With High Dividend Yields Motley Fool
Nov-27-18 08:00AM  Wall Street Wants the Best Patents, Not the Best Drugs Bloomberg
Nov-26-18 07:34PM  Enanta Pharmaceuticals Inc (ENTA) Q4 2018 Earnings Conference Call Transcript Motley Fool
09:49AM  2 Dividend Stocks You'll Wish You'd Bought 32 Years From Now Motley Fool
09:23AM  The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca Zacks
08:25AM  Gilead's HIV Franchise, CAR T Therapy Likely to Propel Growth Zacks
Nov-25-18 05:22PM  2 Cheap Dividend Stocks You Can Buy Right Now Motley Fool
Nov-23-18 05:45PM  FDA Approves Roche Subsidiary's Treatment for Acute Myeloid Leukemia GuruFocus.com
08:58AM  Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs Zacks
Nov-22-18 07:23AM  Roche, AbbVie Get FDA Approval for Venclexta Label Expansion Zacks
Nov-21-18 02:14PM  AbbVie Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy PR Newswire
11:00AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ABBV, MGTI, ACHC, JT and HTHT GlobeNewswire
Nov-20-18 05:45PM  AbbVie (ABBV) Stock Moves -1.55%: What You Should Know Zacks
02:37PM  3 Top Large-Cap Stocks to Buy in November Motley Fool
12:43PM  SHAREHOLDER ALERT: ABBV JT CWH HON DY RYAAY: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
12:37PM  DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
09:27AM  FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline - November 20, 2018 ACCESSWIRE
08:32AM  AbbVie to Highlight Breadth of Innovative Science and Ongoing Commitment to Blood Cancer Patients with New Data From Studies of Ibrutinib and Venetoclax at 2018 American Society of Hematology Annual Meeting & Exposition PR Newswire
07:00AM  Today's Research Reports on Trending Tickers: AstraZeneca and AbbVie ACCESSWIRE
Nov-19-18 03:51PM  Vertex (VRTX) Gets Positive CHMP Opinion for Orkambi in Kids Zacks
12:17PM  CLASS ACTION UPDATE for ABBV and ALNY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
11:41AM  DEADLINE TUESDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
09:30AM  Should Value Investors Consider AbbVie (ABBV) Stock Now? Zacks
09:27AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline November 20, 2018 ACCESSWIRE
Nov-18-18 10:00AM  SHAREHOLDER ALERT: TGTX ABBV MGTI HAS CPB CHGG ADNT GOOG NKTR SYF RBBN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
Nov-17-18 08:36AM  Why Abbvie Is Down 5% in 2018 So Far Motley Fool
Nov-16-18 07:40PM  4-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm ACCESSWIRE
05:43PM  101 Best Dividend Stocks to Buy for 2019 and Beyond Kiplinger
04:25PM  WeissLaw LLP: AbbVie Inc. is the Subject of a Legal Investigation ACCESSWIRE
10:37AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of COCP, ABBV, CHGG, HON and DY GlobeNewswire
09:30AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline - November 20, 2018 ACCESSWIRE
09:00AM  11 NYSE- And NASDAQ-Listed Stocks With Cannabis Exposure Benzinga
08:35AM  Pharma Stock Roundup: FDA Updates on MRK, AZN's Cancer Drugs, Bayer's Q3 Earnings Zacks
Nov-15-18 04:00PM  ABBVIE LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 in AbbVie, Inc. to Contact the Firm ACCESSWIRE
08:10AM  The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results Benzinga
Nov-14-18 07:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline ABBV ACCESSWIRE
05:45PM  AbbVie (ABBV) Gains As Market Dips: What You Should Know Zacks
05:35PM  AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress PR Newswire
04:16PM  CLASS ACTION UPDATE for ABBV, CHGG and HTHT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
03:34PM  AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study Zacks
02:35PM  6-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
01:38PM  November 20th AbbVie Deadline: Bernstein Liebhard LLP Reminds Investors of the Important Upcoming Deadline in the Shareholder Class Action Lawsuit Against AbbVie Inc. - ABBV GlobeNewswire
09:52AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline - November 20, 2018 ACCESSWIRE
08:44AM  The Zacks Analyst Blog Highlights: Berkshire Hathaway, AbbVie, Booking, HCA and Kimberly-Clark Zacks
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune diseases; IMBRUVICA, an oral therapy for treating chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, to treat adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid for hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a treatment for relapsing forms of multiple sclerosis. It serves wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has collaboration with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; International Myeloma Foundation; Calibr and Scripps Research; The Institute for Research in Immunology and Cancer Commercialization of Research; the Universite de Montreal; Tolero Pharmaceuticals, Inc.; Galapagos; Mission Therapeutics Ltd; and Bristol-Myers Squibb Company. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CHASE WILLIAM JEVP, Finance & AdministrationDec 12Sale90.0060,0005,400,000104,863Dec 14 05:12 PM
GONZALEZ RICHARD AChairman of the Board and CEODec 11Sale88.7516,8501,495,438286,203Dec 13 04:56 PM
Schumacher Laura JExecutive Vice PresidentDec 04Option Exercise51.4294,1404,840,679192,398Dec 07 05:15 PM
Schumacher Laura JExecutive Vice PresidentDec 04Sale93.5894,1408,809,55298,258Dec 07 05:15 PM
Gosebruch Henry OEVP, Chief Strategy OfficerNov 29Sale90.1042,4503,824,94030,350Nov 30 05:22 PM
SEVERINO MICHAELEVP, R&D and CSOAug 17Sale97.5250,0004,876,06082,281Aug 21 04:58 PM
TILTON GLENN FDirectorJun 27Buy91.905,400496,27439,735Jun 29 02:30 PM
RAPP EDWARD JDirectorJun 20Buy98.631,01399,90920,743Jun 22 05:56 PM
ALBAN CARLOSEVP, Commercial OperationsMar 01Option Exercise29.2348,1001,405,795178,547Mar 02 05:29 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMar 01Option Exercise25.9132,400839,339197,263Mar 02 05:28 PM
Schumacher Laura JExecutive Vice PresidentMar 01Sale117.8525,0002,946,14898,317Mar 02 05:28 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMar 01Sale114.5032,4003,709,687164,863Mar 02 05:28 PM
ALBAN CARLOSEVP, Commercial OperationsMar 01Sale114.3980,9959,264,80897,552Mar 02 05:29 PM
Michael Robert A.VP, ControllerFeb 28Sale119.434,294512,8536,876Mar 02 05:31 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 28Sale117.771,337157,45893,312Mar 02 05:31 PM
SEVERINO MICHAELEVP, R&D and CSOFeb 28Sale117.932,643311,684132,281Mar 02 05:30 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 28Sale118.6718,1292,151,45217,588Mar 02 05:30 PM
CHASE WILLIAM JEVP, Chief Financial OfficerFeb 28Sale119.4438,5284,601,954164,863Mar 02 05:28 PM
ALBAN CARLOSEVP, Commercial OperationsFeb 28Sale117.852,579303,928130,447Mar 02 05:29 PM
GONZALEZ RICHARD AChairman of the Board and CEOFeb 28Sale117.888,280976,084313,012Mar 02 05:28 PM
Michael Robert A.VP, ControllerFeb 20Sale120.31992119,35113,557Feb 20 06:08 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesDec 18Option Exercise35.8887,0403,122,995113,118Dec 19 06:09 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesDec 18Sale98.4587,0408,569,05326,078Dec 19 06:09 PM
Schumacher Laura JExecutive Vice PresidentDec 15Option Exercise35.881,14341,011106,875Dec 15 05:13 PM